AR017172A1 - Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden - Google Patents

Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden

Info

Publication number
AR017172A1
AR017172A1 ARP980104976A ARP980104976A AR017172A1 AR 017172 A1 AR017172 A1 AR 017172A1 AR P980104976 A ARP980104976 A AR P980104976A AR P980104976 A ARP980104976 A AR P980104976A AR 017172 A1 AR017172 A1 AR 017172A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
lower alkyl
radical
alkyl radical
pharmaceutical compositions
Prior art date
Application number
ARP980104976A
Other languages
English (en)
Original Assignee
Union Pharma Scient Appl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Pharma Scient Appl filed Critical Union Pharma Scient Appl
Publication of AR017172A1 publication Critical patent/AR017172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona que responden a la siguiente formula (I) general, en donde: R representa: un radical alquiloinferior que tiene de 1 a 6 átomos de carbono; un radical haloalquilo inferior que tiene de 1 a 6átomos de carbono, o un grupo -NH2, R1 representa: un átomode hidrogeno, un radical alquilo inferior que tiene de 1 a 6 átomos de carbono o un radical haloalquilo inferior que tiene de 1 a 6 átomos de carbono, Xrepresenta: un átomo de oxígeno, o un átomo de azufre, X1 y X2 independientemente representan: un átomo de hidrogeno, un átomo de halogeno, un radical alquiloinferior que tiene de 1 a 6 átomos de carbono, un radical haloalquilo inferior que tiene de 1 a 6 átomos de carbono, un radical O-alquilo inferior que tiene de1 a 6 átomos de carbono, un radical NR2R3 en donde R2 y R3 independientemente representan un radical alquilo inferior que tiene de 1 a 6 átomos de carbono, oinclusive X1 y X2 juntas pueden formar un grupo dioximetileno, así como sus sales de adicion en particular las sales de adicion farmacéuticamente aceptablescuando X1 y X2 tienen una funcion salificable. Un método para la preparacion de tales derivados y composiciones farmacéuticas que los comprenden. Estoscompuestos poseen propiedades antiinflamatorias y analgésicas siendo bien tolerados.
ARP980104976A 1997-10-07 1998-10-06 Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden AR017172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9712459A FR2769311B1 (fr) 1997-10-07 1997-10-07 Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique

Publications (1)

Publication Number Publication Date
AR017172A1 true AR017172A1 (es) 2001-08-22

Family

ID=9511893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104976A AR017172A1 (es) 1997-10-07 1998-10-06 Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden

Country Status (12)

Country Link
US (1) US5859036A (es)
EP (1) EP1023277A1 (es)
JP (1) JP2001519343A (es)
AR (1) AR017172A1 (es)
AU (1) AU747221B2 (es)
CA (1) CA2306245A1 (es)
CO (1) CO4980887A1 (es)
FR (1) FR2769311B1 (es)
PE (1) PE120099A1 (es)
TW (1) TW520365B (es)
WO (1) WO1999018093A1 (es)
ZA (1) ZA988921B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
JP2003531202A (ja) * 2000-04-25 2003-10-21 ファルマシア・コーポレーション ３，４−ジ（カルボシクリルまたはヘテロシクリル）チオフェンの位置選択的合成
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004522754A (ja) * 2001-02-02 2004-07-29 ファルマシア・コーポレーション 月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐２阻害剤および性ステロイドを使用する方法
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
KR100804827B1 (ko) * 2002-05-17 2008-02-20 씨제이제일제당 (주) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
KR100465455B1 (ko) * 2002-06-24 2005-01-13 씨제이 주식회사 2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4－芳基－5h－噻吩－2－酮衍生物、其制法和用途
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050439A1 (de) * 1970-10-14 1972-04-20 Farbenfabriken Bayer Ag, 5090 Leverkusen Thiazolon-(2)-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
NZ336428A (en) * 1993-11-30 2005-02-25 G use of substituted pyrazolyl benzosulphonamides to treat inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors

Also Published As

Publication number Publication date
WO1999018093A1 (fr) 1999-04-15
ZA988921B (en) 1999-04-12
EP1023277A1 (fr) 2000-08-02
US5859036A (en) 1999-01-12
CO4980887A1 (es) 2000-11-27
FR2769311B1 (fr) 1999-12-24
TW520365B (en) 2003-02-11
PE120099A1 (es) 1999-12-19
AU747221B2 (en) 2002-05-09
JP2001519343A (ja) 2001-10-23
CA2306245A1 (en) 1999-04-15
FR2769311A1 (fr) 1999-04-09
AU9446298A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
AR017172A1 (es) Compuestos derivados de 3,4-diariltiazolina-2-ona o 2-tiona un metodo para su preparacion y composiciones farmaceuticas que los comprenden
BR9912937A (pt) Pró-drogas de inibidores de bomba de prótons
HUP9901074A2 (hu) Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
CY1110240T1 (el) Νεα παραγωγα 2η-πυριδαζινο-3-ονης, φαρμακευτικες συνθεσεις που τα περιεχουν και μεθοδος για την παρασκευη του δραστικου συστατικου
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
NO20054787D0 (no) Indenderivater som farmasotiske midler
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT1233953E (pt) Novos derivados de benzotiadiazinas processo para a sua preparacao e as composicoes farmaceuticas que os contem
AR013608A1 (es) Derivados de 3,4-diariloxazolona, procedimiento para su preparacion, y composicion farmaceutica que los comprende.
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
DK0952159T3 (da) Anvendelse af phenylhydrazonderivater som antiinflammatoriske eller analgetiske midler
DE60322064D1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)-derivate und sie enthaltende zusammensetzungen
AR006301A1 (es) Derivados de oxazolidin-2-ona, procedimiento para prepararlos, medicamento constituido por dicho derivado y composicion farmaceutica que comprende a dicho derivado
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ATE214064T1 (de) Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DK0913151T3 (da) Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel
BR9805014A (pt) Inibidores de metaloproteinase, processo para sua preparação e composições farmacêuticas contendo os mesmos
AR030002A1 (es) Compuestos de benzotiadiazina un proceso para su preparacion y composiciones farmaceuticas que los contienen
ATE358675T1 (de) Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
YU48094B (sh) Derivati fenoksietilamina i postupak za njihovo dobijanje

Legal Events

Date Code Title Description
FB Suspension of granting procedure